IP Library Granted Patent US 11,179,449
Granted Patent B2
US 11,179,449 · App. 15/742,771 · Granted Nov 23, 2021

Immunogenic preprocalcitonin peptides

Inventors: Fathia Mami-Chouaib (Bourg la Reine, FR); Aurélie Durgeau (Orsay, FR)
Assignees: Institut Gustave Roussy; Institut National de la Sante et de la Recherche Medicale; Université Paris-Saclay
A61K39/0011A61K35/15A61K45/06A61P35/00A61K2039/585
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,449
App. No.
15/742,771
Granted
Nov 23, 2021
Kind
B2
Abstract

The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.

Claims (13)

1. A method of antitumor immunotherapy, comprising administering to a human subject an immunogenic composition comprising two peptides chosen from the sequences consisting of SEQ ID NO: 3 and 6, and a pharmaceutically acceptable adjuvant in an amount effective to induce an antitumor immune response in the human subject.

2. The method according to claim 1 , which is for immunotherapy of tumors expressing calcitonin, or of pathologies associated with a high serum level of calcitonin, precalcitonin, or prepro-α-CGRP.

3. The method according to claim 1 , which is for immunotherapy of medullary thyroid carcinoma or pulmonary carcinoma.

4. The method according to claim 1 , which is for immunotherapy of a tumor having cells which do not express TAP peptide transporters.

5. The method according to claim 1 , wherein said human subject is HLA-A*0201 positive.

6. The method according to claim 1 , wherein the immunogenic composition further comprises at least two peptides chosen from the sequences consisting of SEQ ID NOs: 1 to 7.

7. The method according to claim 1 , wherein the immunogenic composition further comprises at least two additional peptides chosen from the sequences consisting of SEQ ID NOs: 1 and 5.

8. The method according to claim 7 , wherein the immunogenic composition comprises at least one additional peptide chosen from the sequences consisting of SEQ ID NO: 2 or 4.

9. The method according to claim 1 , wherein the immunogenic composition comprises a combination of peptides chosen from the combination of sequences consisting of SEQ ID NOs: 1, 2, 3, 5 and 6, the combination of sequences consisting of SEQ ID NOs: 1, 3, 4, 5 and 6, the combination of sequences consisting of SEQ ID NOs: 1, 3, 5 and 6, and the combination of sequences consisting of SEQ ID NOs: 3, 4, 5 and 6.

10. The method according to claim 1 , wherein the immunogenic composition comprises antigen-presenting cells loaded with said peptide sequences.

11. The method according to claim 1 , further comprising administering at least one immune checkpoint inhibitor.

12. The method according to claim 1 , further comprising administering at least one additional peptide chosen from the sequences consisting of SEQ ID NO: 19, 20 or 21.

13. The method according to claim 1 , wherein the immunogenic composition is an antitumor vaccine.

Assignments (3)
MERGER Recorded Aug 17, 2022
From: UNIVERSITE PARIS-SUD
To: UNIVERSITÉ PARIS-SACLAY
Reel/Frame 060831/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2019
From: MAMI-CHOUAIB, FATHIA; DURGEAU, AURELIE
To: INSTITUT GUSTAVE ROUSSY
Reel/Frame 048973/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2018
From: INSTITUT GUSTAVE ROUSSY
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; UNIVERSITY PARIS-SUD
Reel/Frame 045802/0338 →
Priority Claims (1)
EP 15176174 · Jul 9, 2015 · regional
Continuity (1)
Related Publication 20180200355A1 · Jul 19, 2018